{"name":"Sovargen","slug":"sovargen","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNTGJjdHl0YXU5WFhUUlVySHcxX0ZQX2s0WDJWajJ0NndxdWExcTJPX084VXF1S2QyTTZWQkM1ZEU3bFZUckhwWjhna1h1VlE5eXRjUVdUdUl1NmM1Q1RjWUx5cVVwVnlReDNJN2hwNGEybVRwcGxXd1czbUVTV2lOSWtPYUg5NkU1VXRpR21PemtRZ0Q1dVE?oc=5","date":"2026-01-08","type":"deal","source":"The Pharma Letter","summary":"Angelini signs exclusive $550M deal with Sovargen - The Pharma Letter","headline":"Angelini signs exclusive $550M deal with Sovargen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPZGhlaXJlUjZaakRneElXblcwVnhFSDQ0eVhwMTd2YlpDZEJMNkdNdHVseV9lR1h4cnI5cDZBTW9UcTB6NEJ2VkVwM2daWVdXQXVrUDhkamdiNW1zbkd2RjE5NGhUNVltTDVVTjY1SFdxZ0xVU2JLTGhYVDV3MjlzMjc0ZjV2SDlSUHZjUnlQVnFqSXlrRDB1c0dYSklIUWo4Mmc?oc=5","date":"2025-10-29","type":"deal","source":"BioWorld News","summary":"Angelini signs $550M deal for Sovargen’s ASO drug in epilepsy - BioWorld News","headline":"Angelini signs $550M deal for Sovargen’s ASO drug in epilepsy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQQ2xvXzBPVTg1d2N6MEZaYlpRbXFtMjB6ZlhMalhDVDA0dTJiR3ltYmJPaV9keTNhY202Z2lFVVF1TDRYLUVhTkVQOEVzbGw5UGdQQ1JZdnpYclBMSmU5WUEtQ0M3d2FxNFRvZURLMkVMbUZ3RlVXSURWWTJzdnFpaWpWZTVDekZxVlE?oc=5","date":"2025-09-29","type":"pipeline","source":"BioXconomy","summary":"Eyes on Asia: BMS, Mabwell Bioscience, Sovargen - BioXconomy","headline":"Eyes on Asia: BMS, Mabwell Bioscience, Sovargen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTE1IVGgybDJsZGVXbGJPNENLTk10cGpDT251LVpKaFVyTE8tM2RsUDNrV2tOdzZIR2ViUldNZGZESW0xMjFlMk8wcGQxWU8?oc=5","date":"2025-09-25","type":"deal","source":"The Exchange Asia","summary":"Angelini Pharma Partners Sovargen To Develop And Market New Brain Health Asset - The Exchange Asia","headline":"Angelini Pharma Partners Sovargen To Develop And Market New Brain Health Asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxOQ2lQbjRnQmozdXBNWjg1Y3FUU3EtNWdadklra1pZSmtwNGVvZlJIVVpLOHd4TF9SQkgzUTNzOGszNEtnbUJXRzZvQ2NjSXlmUUZOMlE5LTBpN2VrdWR2UjhyTGU3NjBRSnlTZHo1MHlDR0tyMnoxXzdzWkxXN2Z1cVV3?oc=5","date":"2025-09-23","type":"deal","source":"pharmaphorum","summary":"Angelini taps Sovargen for epilepsy drug in $550m deal - pharmaphorum","headline":"Angelini taps Sovargen for epilepsy drug in $550m deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNYnN4VW5mam9NZjRIM2dnSkdBblpGbXdMX1Jld1JrTHV5TnU2dVFBS1BOTVVIU2FlWHNfYjVYRG82QlhaRUc5LW44cExoUE41R1R1RzJWYXplVUdvNVl4UlpfdU5uYXM5ZGQtT1libjVNaFljU29ubV9obEdndVVndXhyWm0tSHd6cUN0ZVNwejBaS29oYWppWk9URHlBcmdrd0J2Uy1uaHdMYkE?oc=5","date":"2025-09-22","type":"pipeline","source":"Fierce Biotech","summary":"Italy's Angelini inks $550M-plus pact for preclinical brain condition asset - Fierce Biotech","headline":"Italy's Angelini inks $550M-plus pact for preclinical brain condition asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPbmNiazdUR2hlQjFCN2xvZ3REN0NhTEw1WjBMUTRNQjdUWDRmNDNYSjJOaDY5d3hHTVYxQzBBZkV2UV9oa0FSMjFORmc5c0lIQWJQT0RhaUtXdlBzYVJ6ZTVFaDlkbW05YU9lVXVMTjA5aHZzY21rMFZfWC1lTGdwYTQ5QXAzbExHRmVZcw?oc=5","date":"2025-09-22","type":"deal","source":"Yahoo Finance","summary":"Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset - Yahoo Finance","headline":"Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Right","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}